Approximately 10–15% of NSCLC patients in North America carry activating mutations in the EGFR gene that impart sensitivity to several tyrosine kinase inhibitors (TKIs) [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.